Darzalex Faspro FDA Approval History
FDA Approved: Yes (First approved May 1, 2020)
Brand name: Darzalex Faspro
Generic name: daratumumab and hyaluronidase-fihj
Dosage form: Injection
Company: Janssen Pharmaceuticals, Inc.
Treatment for: Multiple Myeloma; Light Chain (AL) Amyloidosis
Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a combination of daratumumab (a CD38-directed cytolytic antibody) and hyaluronidase (an endoglycosidase) indicated for the treatment of multiple myeloma and light chain (AL) amyloidosis.
Development Timeline for Darzalex Faspro
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.